Acute Myeloid Leukemia, Adult Clinical Trial
Official title:
A Phase Ib/II, Multi-center, Open Clinical Trial of Crifortinib Besylate Combined With Chemotherapy in Newly-treated Adult Subjects With Acute Myeloid Leukemia
This is a multi-center open clinical study aimed at evaluating the efficacy and safety of Clifutinib Besylate combined with chemotherapy in newly-treated adult subjects with AML
Main purpose:To evaluate the tolerability and safety of Clifutinib Besylate combined with DA (Cytarabine + Daunorubicin) or AZA (Azacitidine) in newly-treated adult AML subjects; explore reasonable therapeutic doses through climbing tests in different dose groups. To evaluate the efficacy of Clifutinib Besylate combined with DA or AZA in newly treated adult AML subjects. Secondary purpose:To observe the pharmacokinetic (PK) characteristics of Clifutinib combined with DA or AZA in newly-treated adult AML subjects and the drug interaction between Clifutinib and AZA at the same time.Observe the correlation of different subtypes and prognostic risk with the efficacy of Clifutinib and the changes of genes before and after treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05601726 -
First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients
|
Phase 1 | |
| Recruiting |
NCT06200441 -
Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Markers in Graft-Versus-Host Disease
|
||
| Recruiting |
NCT04050280 -
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
|
Phase 2 | |
| Recruiting |
NCT06449482 -
Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06252584 -
Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients
|
Phase 1 | |
| Completed |
NCT05988047 -
Analysis of CMTM6 Expression in Patients With Acute Myeloid Leukemia
|
||
| Terminated |
NCT03951961 -
Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation
|
Phase 2 | |
| Enrolling by invitation |
NCT03902665 -
Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75
|
Phase 2 | |
| Not yet recruiting |
NCT06285136 -
Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05127798 -
RWE of 1st Line Treatment in Adults With AML From 18 to 70 Years Old.
|
||
| Recruiting |
NCT05906914 -
Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia
|
Phase 2 | |
| Not yet recruiting |
NCT06199557 -
A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04752527 -
Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features
|
Phase 2 | |
| Recruiting |
NCT03766126 -
Lentivirally Redirected CD123 Autologous T Cells in AML
|
Phase 1 | |
| Recruiting |
NCT05674539 -
Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
|
Phase 3 | |
| Enrolling by invitation |
NCT02985372 -
Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia
|
Phase 3 | |
| Recruiting |
NCT05703126 -
Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML
|
N/A | |
| Recruiting |
NCT04240600 -
Effect of a Hyperproteic Hyperenergetic Enteral Formula on Body Composition and VEGF in AML During Hospital Stay
|
N/A | |
| Terminated |
NCT04425655 -
Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.
|
Phase 2 | |
| Recruiting |
NCT04454580 -
Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy
|